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Diagnosis

Biochemical Diagnosis of Myocardial Infarction
Craig C. Foreback, PhD*
A rapid, sensitive, and specific marker for the diagnosis of acute myocardial infarction (MI) and the
assessment of reperfusion following thrombolytic therapy has heen sought hy research workers for
years. Creatine kinase-MB (CK-MB) is the best biochemical marker currently avaUable to the
cardiologist and the emergency room physician for the assessment of patients presenting with
symptoms of acute Ml. CK-MB is best measured using immunoassay techniques at 3- to 4-hour time
intervals during thefirst 12 hours afier onset of.symptoms. Other currently availahle markers include
lactate dehydrogenase and its isoenzymes and myoglobin. Future developments include assays for
troponin, reported to be a true cardiac-specific marker, and myosin light chains which may have
value in noninvasive infarct sizing. (Heniy Ford Ho.sp MedJ 1991 ;39:159-64)

A

cute myocardial infarction (MI) is one ofthe consec|uences
of severe atherosclerosis resulting in ischemia of the cardiac muscle. In its most severe form the blood supply may be
completely blocked, leading to intense chest pain that is often
described as crushing or tightness. Other symptoms include
nausea and vomiting, profuse sweating, and pain radiating to the
arms, wrists, or jaw. Blood pressure and heart rhythm may be
normal or the patient may be in circulatory sbock. Suspected
acute M I results in over 4 million hospital admissions each year
in the United States alone. Approximately 1.3 million cases of
acute M I are diagnosed each year, resulting in 600,000 deaths.
With the average cost of a cardiac care unit (CCU) bed approaching $1,000 per day and considering that CCU bed space
is always at a premium, there is intense interest in appropriate
diagnosis and treatment of acute M I .
Clinical suspicion of acute M I affects both short- and longterm management decisions. Attempts to salvage myocardium
through reperfusion should be made in the first 4 to 6 hours from
the onset of infarcfion. Thus, pafients presenting to the emergency room present a diagnostic dilemma.
With many patients, history and symptoms cleariy indicate
that a M I has occurred. The ECG often firmly establishes the diagnosis. The ECG can show changes characteristic of acute M I ,
such as changes in the ST segment and appearance of Q waves
and T waves, provided the ECG has been normal previously.
Because these specific changes can sometimes be obscured by
previous cardiac events or may not appear at all (Q waves do not
appear in subendocardial infarctions), the diagnosfic sensifivity
ofthe ECG can be as low as 62%, although its diagnostic specificity is neariy 100%. Nearly 50% of patients with an acute M I
present to emergency departments with nondiagnostic ECGs.
About 25% ofall acute Mls may be clinically silent, associated
with atypical symptoms or no symptoms. Many patients with
silent infarcts are diabetic and their lack of pain is attributed to
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the autonomic neuropathy associated with a long history of diabetes. In elderiy patients acute M I often presents with sudden
shortness of breath, confusion, fainting, or even a stroke. In
those cases where history is atypical and/or the ECG pattem is
equivocal, the clinician must rely on serum enzymes and other
biochemical tests.

Laboratory Testing in Myocardial Infarction
Historically, creatine kinase (CK), aspartate transaminase
(AST) (glutamic-oxaloacetic transaminase), and lactate dehydrogenase (LD) were the key enzymes used in the investigation
of M I . Typically all three of these enzymes would be measured
at periodic intervals for up to three days following a suspected
acute M l . With the availability of isoenzyme determinations,
requests for cardiac enzymes now include CK and LD isoenzymes. AST is no longer recommended as part of a cardiac profile; indeed, most experts agree that the isoenzymes of CK and
in certain cases LD should be determined following acute M I . It
is clear that CK-MB has become the most important serum enzyme test used in the diagnosis of acute M I . Other important
markers which are utilized or under study for the diagnosis of
acute M I include troponin, myosin light chains, and myoglobin.

Troponin
Although CK-MB is the best currentiy available marker for
acute M I , it does have limitations. CK-MB can be elevated after
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skeletal muscle injury as the skeletal muscle regenerates. Another shortcoming of CK-MB measurement is that cardiac CKMB retums to normal within 24 hours after the event. Thus patients admitted to the hospital two or three days postinfarction
will likely have normal CK-MB.
A better marker for acute MI would be present only in cardiac
tissue, would be released within a few hours of the event, and
would remain elevated for days rather than hours. Recent studies have shown that certain elements of the troponin complex
may meet these desired characteristics.
Troponin is a complex of three nonidentical polypeptides:
troponin C (TnC) which binds calcium, troponin T (TnT) which
binds tropomyosin, and troponin I (Tnl) which inhibits ATPase
activity. Each of the different subunits of troponin occurs in various isoforms according to the muscle type of its origin. TnC is
known to exist in cardiac and fast-twitch (short duration action
potential or fast channel activation of contractile machinery in
skeletal muscle) skeletal isoforms. The slow-twitch (long duration action potential or slow channel activation) isoform appears
to be identical to cardiac TnC and has been found in fibroblasts.
Thus TnC is not specific for detection of myocardial injury.
Tni and TnT are known to exist in cardiac as well as slowtwitch and fast-twitch skeletal muscle forms. Their rapid release
from ischemic muscle coupled with their cardiospecificity make
them excellent candidates for laboratory markers of acute MI.
Cummins and associates (1) described the first radioimmunoassay (RIA) for cardiac Tnl measurement. Thirty-two patients
known to have had acute MI exhibited elevated Tnl values 4 to
6 hours after the onset of chest pain. The early release pattem of
cardiac Tnl following acute MI was similar to the release of CKMB: however, Tnl remained elevated for more than four days.
In another report, Cummins et al (2) carried out a comparative
study of total CK, CK-MB, myoglobin, tropomyosin, and cardiac Tnl. Only the mean cardiac Tnl remained normal in marathon mnners following a race.
Bodor et al (3) have described monoclonal antibodies for cardiac Tnl. Preliminary results of these assays using these antibodies have been published.
Katus et al (4) have recentiy evaluated an enzyme-linked immunoadsorbent assay for the other cardiac-specific troponin,
TnT. The method is based on a pair of monoclonal/polyclonal
antibodies. Elevated TnT levels were found in acute MI patients
as early as 3 hours postinfarction. Values remained elevated for
up to three weeks.
These studies strongly suggest that troponin I or troponin T
measurements have promise as biochemical markers for the diagnosis of acute MI. What we need now is a commercially available, rapid, monoclonal-based assay. At least one manufacturer
claims to be developing such tests. This would allow testing on
a large number of patients, leading to the description of the release characteristics of the troponin molecule following myocardial ischemia and reperfusion of myocardium.

Myosin light chains
Myofibrillar proteins such as myosin are major constituents
of muscle. In 1978 Trahem and coworkers (5) reported on the

160

Henry Ford Hosp Med J—Vol 39. Nos 3 & 4.1991

diagnosis of acute MI by immunological detection of myosin
light chains in semm.
Myosin light chains are located at each amino-terminal part
of the myosin heavy chain molecule. The amino terminal ends
form the globular myosin heads which interact reversible with
actin during contraction. During acute MI, myosin light chains
are released continuously within 3 hours after the onset of pain
and for at least two and in some cases more than three weeks.
The kinetics of myosin light chain release are clearly different
from cytosolic molecules like myoglobin or CK. Serum concentration of myosin light chains is not affected by reperfusion of
the infarct zone. Thus cardiac myosin light chains may be particularly useful for the estimation of infarct size in either the nonreperfused or the reperfused patient.
A cardiac-specific light chain assay may not be achievable,
however. There is evidence that the "cardiac" myosin light
chain-1 isoform may also be expressed in slow-twitch skeletal
muscle. Differentiation of cardiac and skeletal muscle damage
may not be possible even with a highly specific anticardiac
myosin light chain antibody.
Cardiac myosin light chain measurements allow sensitive detection of myocardial cell damage over an extended period of
time and can be used as an indicator of infarct size. However, the
lack of cardiac specificity of these assays may reduce its effectiveness as a biochemical marker in acute MI. The role of myosin light chain assays remains to be elucidated.

Myoglobin
Of all the markers of tissue necrosis discussed herein, myoglobin is one of the earliest to appear in the circulafion. It also
normalizes quickly after acute Ml. Thus, myoglobin can be useful for detection of infarct extension or reinfarction. Recently
developed methods for myoglobin are reliable and reasonably
rapid.
In the absence of fibrinolytic therapy, serum myoglobin
reaches levels above the upper limit in 3 to 4 hours. Maximum
concentrations are reached in 8 to 12 hours. Peak values are followed by a rapid decrease in concentration, retuming to normal
within 24 to 36 hours. As with other tissue markers, myoglobin
release is accelerated by fibrinolytic therapy.
While myoglobin appears to be useful during the early phases
of an acute MI, it has some drawbacks, particularly its lack of organ specificity as myoglobin is found in both cardiac and skeletal muscle. Myoglobin concentrations increase after intensive
exercise in nearly all individuals. Impaired renal function is also
a factor responsible for an increase in myoglobin levels.
Because of its nonspecificity and because myoglobin levels
are so transient, the use of myoglobin as a marker of MI is limited. It may, however, be extremely useful for the early diagnosis of an acute Ml in patients who are hospitalized shortly after
the onset of chest pain where trauma is not a factor. Current RIA
methods for myoglobin determinations still restrictfimelyavailability of data to the clinician. New methods that employ latex agglutination are currently under study. Such methods will
make possible automated techniques that will provide results in
a few minutes.
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Creatine Kinase, Lactate Dehydrogenase,
and Their Isoenzymes
Creatine kinase
CK is a dimeric enzyme composed of two subunits and has a
molecular weight of 82,000. The subunits are the result of two
distinct structural genes and are labeled M (muscle) and B
(brain). These can then form three different isoenzymes: BB
(CK-1), MB (CK-2), and MM (CK-3). Thetissuedistribution of
the various isoenzymes is shown in Table 1. Other forms of CK
have been reported including macro-CK, mitochondrial CK,
and CK-MM and MB variants. Macro-CK is actually CK-1 associated with IgG. Mitochondrial CK is not related to either the
M or the B subunit and is produced by a separate gene. A macroCK type 2 has been reported and is a polymer of mitochondrial
CK having a molecular weight of > 300,000 Daltons. At least
three MM and two MB variants (isoforms) have been reported
in semm following acute MI (6,7). Once released into the bloodstream, CK loses terminal amino acids by the action of carboxypeptidase-N present normally in the circulation yielding the different isoforms. This metabolism continues resulting in fractions which do not exhibit enzymatic activity. These isoforms,
especially the MB isoforms, reportedly are useful in the early diagnosis of acute MI (8,9). The MM-3 isoform is said to be useful
in assessing reperfusion following thrombolysis (10).
Separation and quantitation of CK isoenzymes
Over the last two decades three viable approaches have been
described for the separation and quantitation of CK isoenzymes:
electrophoresis, ion exchange chromatography, and immunological procedures.
Electrophoresis was the first method to achieve popularity in
clinical settings and continues to be a popular procedure accounting for 40% of current practice. Separation on agarose or
cellulose acetate has been used to separate the CK isoenzymes
satisfactorily. The bands can be visualized by incubating the
support with a concentrated solution of CK assay mixture following separation. The NADPH formed in the reaction is quantitated byfiuorescentdensitometry, which can detect activities
as low as 2 to 5 U/L. Electrophoresis can detect many abnormal
CK bands. Using isoelectric focusing techniques, CK can be
separated into at least three different MM isoforms and two MB
isoforms. The isoforms of CK are reported to be useful in three
areas related to acute MI: early diagnosis, dating of onset, and
determination of reperfusion.
Ion exchange chromatography can also separate CK isoenzymes. Ion exchange chromatography was a popular technique
in the mid to late 1970s and is employed today in many laboratories combined with immunoinhibition on the Dupont aca clinical analyzer. DEAE-Sephadex A50, usually in the form of a
mini-column holding about 60 mg of gel, is most commonly
u.sed and is available in commercial prepacked columns. CK
isoenzymes are absorbed onto the gel. The gel is then washed
and the CK-3 is eluted with 50 mmol/L, pH 8.0 Tris buffer containing 100 mmol/L NaCl. CK-MB is eluted next with the same
Tris buffer containing 200 mmol/L NaCl. Finally CK-BB is
eluted with Tris buffer, 50 mmol/L, pH 7.0 containing 500
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Table 1
Tissue Localization of CK Isoenzymes
Isoenzyme
BB

MB

MM

Tissue
Brain
Smooth muscle
Thyroid
Lung
Prostate
Cardiac muscle
Tongue
Diaphragm
Skeletal muscle (trace amounts)
Skeletal muscle
Cardiac muscle

CK = creatine kinase,

mmol/L NaCl. Since the elution process dilutes the CK isoenzymes, it is important to use small volumes of elution buffer
and/or the eluate as part of the solvent used for reconstitution of
the CK reagents. The method is capable of detecting 1 to 5 U/L.
It is relatively simple to perform but in the presence of high CKMM there is a greaterriskof carryover into the CK-MB fraction.
Immunological procedures such as immunoinhibition, immunoinhibition combined with immunoprecipitation, and enzyme
immunoassay (EIA) are becoming increasingly popular. EIAs
measure enzyme mass and are reported to be more sensitive than
activity measurements. Immunological methods for CK isoenzymes usually require specific antisera against the M or the B
subunits; however, immunoassays specific for MM isoforms
have been reported. Many of the newer methods for CK-MB
employ monoclonal antibodies against the entire MB molecule.
Rabbit antisera can be used to precipitate specific isoenzymes
out of solution in immunoprecipitation. They can also be used to
competitively bind specific isoenzymes in immunoassay techniques. Immunoinhibition methods are more effective when
goat antisera are employed as specific subunit inhibitors. Immunoinhibition and immunoprecipitation techniques measure residual enzyme activity while immunoassays such as RIA or EIA
measure enzyme mass. Immunoassays can determine enzyme
mass even when catalytic activity is lost. EIA orfluorescentimmunoassay using a "sandwich" technique is currentiy the most
popular of the immunoassay approaches. These immunoassays
reportedly have higher analytical sensitivity than do methods
that measure catalytic activities; however, it cannot be assumed
that the diagnostic sensitivity is also better. Reports have shown
diagnostic efficiency to be somewhat better than conventional
methods of quantitation. There are several automated immunoassays now available such that labor requirements are less
than the traditional methods, thereby offsetting the higher reagent costs.
Controversy exists primarily around which separation and
quanfitafion technique is preferred. As previously mentioned,
electrophoretic techniques for the identification and quantitation of cardiac isoenzymes are still widely used. Electrophoresis
provides useful clinical data for the confirmation of acute Ml,
and recent advances in instrumentation, although expensive,
have led to complete automation, allowing high throughput
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with minimal labor. Electrophoretic methods generally are performed only during routine working hours in relatively large
batches due to their complexity.
The immunoprecipitation and/or immunoinhibition techniques are widely used for LD and CK isoenzymes and their
clinical utility has been demonstrated. In particular, the Roche
Isomune procedures have been validated in a clinical setting.
Immunoinhibition CK-MB assays without immunoprecipitation can potentially have a higher incidence of false-positive results because they are subject to interference from the CK-BB
isoenzyme. While the presence of CK-BB in the general population is observed infrequently in those suspected of having acute
MI, it can make a significant contribufion to the rate of falsepositives when using non-MB specific methods.
EIAs have become realistic altematives for identifying and
quanfitafing CK-MB. They are specific and analyfically more
sensitive than previously described techniques. Currentiy available instrumentation has completely automated these assays
such that the technical labor is no longer a disadvantage of the
technique. Reagent costs are still substantially higher than conventional techniques, but the ease of performance has substantially reduced technical labor requirements and improved tumaround time.
Any of the methods described can provide clinically useful
data. The choice of method depends on a number of factors including total test volume, available personnel, tumaround time
requirements, and instrumentation available. Numerous reports
now document that the newer EIAs are much more sensitive
than electrophoresis or other activity-based assays. Consequently they are able to detect acute Ml sooner than other methods.
Regardless of the method employed, it is universally accepted
that interpretation of isoenzymes cannot be done at a single
point in time and is reliable only when serial specimens are
viewed simultaneously. Specimens should be collected on admission and then every 8 hours for 24 to 48 hours. A typical rise/
fall curve as shown in Fig I is diagnostic of acute MI.
There is increasing evidence, however, that with the newer
immunoassays sampling intervals should be shortened such that

20

30

Time (hrs)
Fig 1—CK-MB concentration in myocardial Infarction.
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Table 2
Early Detection Capability of Immunoassays*
Patients Meeting
Laboratory Criteria
After Just 2 Assays
Non-acute M I
Acute M I

96%
100%

Patients Meeting
Laboratory Criteria
Only After 3 Assays
4%
0%

Differences Between Assays

Non-acute M l
Acute M I

1 &2

2&3

l.l
52

0,7
IS

*From Elwart DM. Shimkovilz KL, Minimum number of CK-MB assays necessary to
confirm or rule oul a diagnosis of acute myocardial infarction. Poster presenlalion, Michigan Society of Medical Technology, Annual Meeting, May 2, 1991, Used with permission,
MI = myocardial infarction.

two or three samples would be drawn in the first 8 hours following the event. Two recent studies have suggested that acute MI
can be diagnosed within the first 8 hours using the newer EIA
techniques (11,12). As shown in Table 2, CK-MB measured by
immunoassays can differentiate acute MI patients from nonacute MI patients much earlier than previously thought possible.
These data show that 96% of the patients with acute MI were
properly diagnosed with only two specimens drawn at 8-hour
intervals. Studies by Gibler et al (11) indicate that diagnosis of
acute MI can be made in the first 6 hours after symptom onset
using 3-hour sampling intervals. Clearly, the use of immunoassays, such as the Stratus assay used at Henry Ford Hospital,
which measure CK-MB mass are preferred to previously employed methods.
Lactate dehydrogenase
LD is a tetramer having a molecular weight of 134,000. The
subunits can be of two types, M or H, each under separate genetic control. The resulting combinations produce five different
isoenyzmes: LD-1 (H4), LD-2 (H3M), LD-3 (H2M2), LD-4
(HM3), and LD-5 (M4). The isoenzymes of LD are often referred to in terms of their electrophoretic mobility. The fastest
(toward the anode) migrating enzyme is LD-1 and the slowest is
LD-5 when separated in an alkaline medium. A sixth LD isoenzyme, LD-X, has been described. It is composed of four X subunits and is present in postpubertal human testes. Lactate dehydrogenase is widely distributed throughout the body but is
found only in the cytoplasm of the cell. It is present in the liver,
heart, kidney, striated muscle, red blood cells, and lung fissue.
The isoenyzmes of LD are somewhat specific in their distribution as shown in Table 3.
Historically, methods for the separation of LD isoenyzmes
were available much earlier than were procedures for the identification of the CK isoenyzmes. Electrophoretic separation and
relative quantitation on agarose gels or cellulose acetate membranes is most commonly used. Electrophoretic separation of
LD isoenzymes is effective, relafively accurate, and still widely
used in many clinical laboratories. Immunological separations
have also become increasingly popular. Since there are many
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Table 3
Tissue Localization of LD Isoenzymes
Isoenzyme

Tissue

LD-1, LD-2

Heart
Kidney
Brain
Red blood cells
Thyroid
Adrenal gland
Lymph nodes
Pancreas
Thymus
Spleen
Leukocytes
Liver
Skeletal muscle

LD-3

LD-4. LD-5
LD = lactate dehydrogenase.

acceptable variations for the electrophoretic separation and
quantitation of LD isoenzymes, a somewhat generic procedure
is described here. Agarose gels are most popular but cellulose
acetate is acceptable. Quantitation is by densitometric scanning
with visible orfluorescentdetection. Following the separation at
pH 8.6 to 8.8, a reaction mixture is layered over the separation
medium. The reaction mixture contains L (-F) lactate, NAD, and
is buffered at pH 9.0 to 9.2. After the reaction has incubated at
37° to 40° C, the plates are dried at 65° C. Afluorescentscanner
is used to determine the relativefluorescencefollowing excitation at 340 nm. If afluorescentscanner is not available, procedures incorporating dye coupled reactions (to NADH) can be
used. Fluorescent scanning results in more uniform bands than
does visual scanning.
The other widely used approach is based on the precipitation
of M-subunit containing LD isoenzymes. This technique allows
specific quantitation of the LD-1 or H^ isoenzyme. It is much
simpler than electrophoresis and has a definitive normal range.
LD isoenzymes are ordered almost exclusively for the purpose
of confirming acute Ml. Thus, the fact that other LD fractions
are not identified and quanfitated is not a serious limitafion. The
procedure is avatiable from Roche Diagnosfics in kit form.
Concem exists over the necessity of evaluating CK and LD
isoenzymes simultaneously. Most reports have recommended
that both be done. However, recent studies suggest that CK-MB
alone is highly sensitive and specific for acute MI (13,14). Assaying LD isoenzymes or LD-1 adds nothing to the diagnostic
efficiency of laboratory testing. Laboratory determination of
LD isoenzymes may be helpful when specimens for analysis
have not been obtained within the first 24 hours following a suspected acute MI.
Testing guidelines
The following testing and interpretation guidelines are relative to cardiac enzyme assays:
Ifthe patient is seen within 24 hours of a suspected event, obtain total CK and CK-MB levels upon admission and then every
eight hours for 24 to 48 hours. The admission specimens can be
considered baseline levels if obtained within the first 2 hours. If
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several posifives are observed on successive specimens, the protocol can be discontinued.
If the patient is not seen within the first 24 hours, both CKMB and LD-1 (or isoenzymes) should be ordered. In this case
LD-1 > 85 or LD-l/LD-2 > 1.0 is consistent with the diagnosis
of acute MI even in the presence of negative CK-MB.
In cases involving skeletal muscle trauma or cmsh injuries,
CK-MB may be positive but usually witi not exceed 3% of the
total CK. When using immunoassays which measure mass
units, a CK-MB/total CK ratio can be used. At our institution a
ratio < 3 is indicative of skeletal muscle injury. The LD-l/LD-2
ratio will be < 1.0 and LD-1 will remain normal, i.e., < 85 lU/L
or < 25% of total LD.
In all cases, cardiac enzymes cannot be interpreted on the basis of a single specimen collection. A single positive or negattve
value is not indicative of the presence or absence of acute MI. A
confirmatory diagnosis can only be made using at least two but
preferably three specimens serially drawn at 8-hour intervals.
Hemolysis of any source can elevate LD-1. CK-MB will not
be affected unless hemolysis is severe and then only if activity
assays are used.
Standard testing guidelines such as those described should
be followed to insure appropriate management of patients suspected of MI. Table 4 summarizes evaluation criteria of laboratory data for the diagnosis of acute MI. CK-MB mass assays are
also reported to be useful in evaluating thrombolytic therapy
(15). A rapid rise in CK-MB following the initiation of thrombolytic therapy indicates successful reperfusion. This rapid washout of CK-MB is illustrated in Fig 2.

Conclusion
Currentiy CK-MB is the best marker routinely available for
the diagnosis of MI. The new EIAs which measure mass are
more sensitive than previously available methods. They are capable of detecting acute MI sooner and have proven to be valuable in the assessment of thrombolytic therapy. Thus, the new
EIAs are recommended as the method of choice for CK-MB
measurement but with significantly reduced fime intervals between analyses.
Of the LD isoenzymes, only LD-1 is of value in acute MI.
Specific measurement of LD-1 by immunoprecipitafion is the

Table 4
Laboratory Criteria for Diagnosis of Acute MI
To Confirm Acute MI:
• At least one of three consecutive CK-MB assays > 5 ng/mL and CK-MB
index > 3, or
• > 50% increase in successive determinations, or
• Rise/fall curve with a peak at 12-20 hours.
To Rule Out Acute MI:
• At least three consecutive negative CK-MB determinations over the first 24hour period following onset of symptoms, or
• LD-1 < 85 lU/L or < 35% of total LD 24-72 hours afler onset of symptoms,
MI = myocardial infarction.
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Time (hrs)

Fig 2—CK-MB following successful repeifusion.
preferred method. LD-1 should only be measured in late admissions.
CK-MM and CK-MB isoforms are reported to have clinical
utility in the diagnosis of acute MI, infarct sizing, and assessment of reperfusion. Currently only electrophoretic methods
can determine all of the various isoforms, limiting the timely
availability of these analyses. Furthermore, the sensitivity of the
isoforms has not been demonstrated to be better than EIAs for
total CK-MB.
Troponin and myosin light chains are biochemical markers
which show promise in the diagnosis and evaluation of acute
MI. Troponin appears to be the long sought cardiac-specific assay. Myosin light chains may be of value in assessing infarct
size. Commercialization of these methods will allow widespread evaluation of the clinical usefulness ofthese analyses.
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